STOCK TITAN

[Form 4] CHEMED CORP Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

Chemed Corp (CHE) executive vice president Spencer S. Lee reported a stock option grant. On 10/21/2025, he received 12,759 stock options with an exercise price of $443.79 per share, expiring on 10/21/2030. The options vest in three equal annual installments beginning 10/21/2026. Following this grant, he beneficially owned 28,196 derivative securities, held directly.

Chemed Corp (CHE) il vicepresidente esecutivo Spencer S. Lee ha riferito una concessione di stock option. Il 21/10/2025 ha ricevuto 12,759 stock option con un prezzo di esercizio di $443,79 per azione, in scadenza il 21/10/2030. Le opzioni vestono in tre rate annuali uguali a partire dal 21/10/2026. A seguito di questa concessione, detiene beneficiamente 28,196 strumenti derivati, detenuti direttamente.

Chemed Corp (CHE) vicepresidente ejecutivo Spencer S. Lee informó una concesión de opciones sobre acciones. El 21/10/2025 recibió 12,759 opciones sobre acciones con un precio de ejercicio de $443.79 por acción, con vencimiento el 21/10/2030. Las opciones se consolidan en tres anualidades iguales a partir del 21/10/2026. Tras esta concesión, posee beneficiosamente 28,196 valores derivados, mantenidos directamente.

Chemed Corp (CHE) 경영 부사장 Spencer S. Lee가 주식매입 옵션 부여를 보고했습니다. 2025년 10월 21일 그는 주당 행사 가격 443.79달러12,759주의 주식 매입 옵션을 받았으며 만료일은 2030년 10월 21일입니다. 이 옵션은 2026년 10월 21일부터 매년 같은 비율로 3회에 걸쳐 vest됩니다. 이 부여 이후 그는 유리하게 28,196개의 파생증권을 직접 보유하고 있습니다.

Chemed Corp (CHE) le vice‑président exécutif Spencer S. Lee a signalé une attribution d'options d'achat d'actions. Le 21/10/2025, il a reçu 12 759 options d'achat avec un prix d'exercice de 443,79 $ par action, expirant le 21/10/2030. Les options s'acquièrent par vesting en trois versements annuels égaux à partir du 21/10/2026. Suite à cette attribution, il détient avantageusement 28 196 titres dérivés, détenus directement.

Chemed Corp (CHE) Vorstandsvizepräsident Spencer S. Lee meldete eine Zuteilung von Aktienoptionsrechten. Am 21.10.2025 erhielt er 12.759 Aktienoptionen mit einem Ausübungspreis von 443,79 $ je Aktie, Ablauf am 21.10.2030. Die Optionen vesten in drei gleichen jährlichen Raten ab dem 21.10.2026. Nach dieser Zuteilung besitzt er rechtlich vorteilhaft 28.196 derivative Wertpapiere, direkt gehalten.

Chemed Corp (CHE) أبلغ نائب الرئيس التنفيذي Spencer S. Lee عن منح خيار أسهم. في 21/10/2025 تلقّى 12,759 خياراً لأسهم مع سعر ممارسة قدره $443.79 للسهم، وتنتهي في 21/10/2030. تت محسّن خيارات إلى vesting على ثلاث دفعات سنوية متساوية ابتداءً من 21/10/2026. عقب هذا المنحة، كان يمتلك مصلحة 28,196 ورقة مالية مشتقة، مملوكة مباشرة.

Positive
  • None.
Negative
  • None.

Chemed Corp (CHE) il vicepresidente esecutivo Spencer S. Lee ha riferito una concessione di stock option. Il 21/10/2025 ha ricevuto 12,759 stock option con un prezzo di esercizio di $443,79 per azione, in scadenza il 21/10/2030. Le opzioni vestono in tre rate annuali uguali a partire dal 21/10/2026. A seguito di questa concessione, detiene beneficiamente 28,196 strumenti derivati, detenuti direttamente.

Chemed Corp (CHE) vicepresidente ejecutivo Spencer S. Lee informó una concesión de opciones sobre acciones. El 21/10/2025 recibió 12,759 opciones sobre acciones con un precio de ejercicio de $443.79 por acción, con vencimiento el 21/10/2030. Las opciones se consolidan en tres anualidades iguales a partir del 21/10/2026. Tras esta concesión, posee beneficiosamente 28,196 valores derivados, mantenidos directamente.

Chemed Corp (CHE) 경영 부사장 Spencer S. Lee가 주식매입 옵션 부여를 보고했습니다. 2025년 10월 21일 그는 주당 행사 가격 443.79달러12,759주의 주식 매입 옵션을 받았으며 만료일은 2030년 10월 21일입니다. 이 옵션은 2026년 10월 21일부터 매년 같은 비율로 3회에 걸쳐 vest됩니다. 이 부여 이후 그는 유리하게 28,196개의 파생증권을 직접 보유하고 있습니다.

Chemed Corp (CHE) le vice‑président exécutif Spencer S. Lee a signalé une attribution d'options d'achat d'actions. Le 21/10/2025, il a reçu 12 759 options d'achat avec un prix d'exercice de 443,79 $ par action, expirant le 21/10/2030. Les options s'acquièrent par vesting en trois versements annuels égaux à partir du 21/10/2026. Suite à cette attribution, il détient avantageusement 28 196 titres dérivés, détenus directement.

Chemed Corp (CHE) Vorstandsvizepräsident Spencer S. Lee meldete eine Zuteilung von Aktienoptionsrechten. Am 21.10.2025 erhielt er 12.759 Aktienoptionen mit einem Ausübungspreis von 443,79 $ je Aktie, Ablauf am 21.10.2030. Die Optionen vesten in drei gleichen jährlichen Raten ab dem 21.10.2026. Nach dieser Zuteilung besitzt er rechtlich vorteilhaft 28.196 derivative Wertpapiere, direkt gehalten.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
LEE SPENCER S

(Last) (First) (Middle)
2500 CHEMED CENTER
255 EAST 5TH STREET

(Street)
CINCINNATI OH 45202

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
CHEMED CORP [ CHE ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
executive vice president
3. Date of Earliest Transaction (Month/Day/Year)
10/21/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (right to buy with tandem tax withholding) $443.79 10/21/2025 A 12,759 (1) 10/21/2030 Capital Stock 12,759 $443.79 28,196 D
Explanation of Responses:
1. Vesting in three equal annual installments commencing 10/21/2026
Spencer S. Lee 10/22/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did CHE’s executive report on Form 4?

An option grant of 12,759 shares at an exercise price of $443.79 per share.

Who is the reporting person in CHE’s Form 4?

Executive vice president Spencer S. Lee.

When do the CHE options vest?

They vest in three equal annual installments starting 10/21/2026.

What is the expiration date of the CHE options?

The options expire on 10/21/2030.

How many derivative securities did the officer hold after the transaction?

He beneficially owned 28,196 derivative securities after the grant.

What is the issuer and ticker in this filing?

The issuer is Chemed Corp with ticker CHE.
Chemed Corp

NYSE:CHE

CHE Rankings

CHE Latest News

CHE Latest SEC Filings

CHE Stock Data

6.34B
14.29M
1.98%
97.98%
2.82%
Medical Care Facilities
Services-home Health Care Services
Link
United States
CINCINNATI